SV2001000465A - Combinacion de secretagogos de hormona del crecimiento y antidepresivos ref. pc10733/20144/bb - Google Patents
Combinacion de secretagogos de hormona del crecimiento y antidepresivos ref. pc10733/20144/bbInfo
- Publication number
- SV2001000465A SV2001000465A SV2001000465A SV2001000465A SV2001000465A SV 2001000465 A SV2001000465 A SV 2001000465A SV 2001000465 A SV2001000465 A SV 2001000465A SV 2001000465 A SV2001000465 A SV 2001000465A SV 2001000465 A SV2001000465 A SV 2001000465A
- Authority
- SV
- El Salvador
- Prior art keywords
- inhibitors
- antidepressants
- cases
- medical procedure
- treatment
- Prior art date
Links
- 239000000935 antidepressant agent Substances 0.000 title abstract 3
- 229940005513 antidepressants Drugs 0.000 title abstract 3
- 102000018997 Growth Hormone Human genes 0.000 title abstract 2
- 108010051696 Growth Hormone Proteins 0.000 title abstract 2
- 239000000122 growth hormone Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 6
- 239000003112 inhibitor Substances 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004217 heart function Effects 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 230000006996 mental state Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
ESTA INVENCION ESTA DIRIGIDA A COMBINACIONES QUE COMPRENDEN UN SECRETAGOGO DE HORMONA DEL CRECIMIENTO, UN PROFARMACO DE ESTE O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL CITADO SECRETAGOGO DE LA HORMONA DEL CRECIMIENTO O DEL CITADO PROFARMACO Y UN ANTIDEPRESIVO, UN PROFARMACO DE ESTE O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL CITADO ANTIDEPRESIVO O DEL CITADO PROFARMACO Y A COMPOSICIONES FARMACEUTICAS Y ESTUCHES QUE COMPRENDEN DICHAS COMBINACIONES. LOS ANTIDEPRESIVOS DENTRO DEL ALCANCE DE ESTA INVENCION INCLUYEN INHIBIDORES DE LA RECAPTACION DE NOREPINEFRINA (POR EJEMPLO COMPUESTOS TRICICLICOS CON AMINA SECUNDARIA O TERCIARIA), INHIBIDORES SELECTIVOS DE LA RECAPTACION DE SERTRALINA, AGENTES QUE SON INHIBIDORES DE LA RECAPTACION DE NOREPINEFRINA/SERTRALINA COMBINADOS, INHIBIDORES DE MONOAMINOOXIDASA Y ANTIDEPRESIVOS ATIPICOS. ESTA INVENCION ESTA DIRIGIDA TAMBIEN A PROCEDIMIENTO DE MEJORA DEL ESTADO FISICO Y/O PSICOLOGICO DE UN PACIENTE SOMETIDO A UN PROCEDIMIENTO MEDICO, A PROCEDIMIENTOS DE TRATAMIENTO DE LA FRAGILIDAD MUSCULOSESQUELETICA, A PROCEDIMIENTOS DE TRATAMIENTO DE LA INSUFICIENCIA CARDIACA CONGESTIVA Y A PROCEDIMIENTOS DE ATENUACION DE LA RESPUESTA CATABOLICA PROTEINICA DESPUES DE UNA OPERACION IMPORTANTE, QUE COMPRENDE LA ADMINISTRACION DE DICHA COMBINACION. PARTICULARMENTE, ESTA INVENCION SE REFIERE COMPOSICIONES Y ESTUCHE TALES QUE MEJORAN LA FUNCION CARDIACA, EL METABOLISMO, EL TONO MUSCULAR Y/O EL ESTADO MENTAL DE PACIENTES SOMETIDOS A UN PROCEDIMIENTO MEDICO. LAS COMPOSICIONES Y ESTUCHES DE ESTA INVENCION SON TAMBIEN UTILES PARA EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL EN PACIENTES A UN PROCEDIMIENTO MEDICO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20701700P | 2000-05-25 | 2000-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2001000465A true SV2001000465A (es) | 2001-07-03 |
Family
ID=22768871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2001000465A SV2001000465A (es) | 2000-05-25 | 2001-05-24 | Combinacion de secretagogos de hormona del crecimiento y antidepresivos ref. pc10733/20144/bb |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20020002137A1 (es) |
| EP (1) | EP1284753A2 (es) |
| JP (1) | JP2003534294A (es) |
| AR (1) | AR028620A1 (es) |
| AU (1) | AU2001255013A1 (es) |
| BR (1) | BR0111002A (es) |
| CA (1) | CA2408036A1 (es) |
| DO (1) | DOP2001000154A (es) |
| EC (1) | ECSP014082A (es) |
| GT (1) | GT200100089A (es) |
| MX (1) | MXPA02011554A (es) |
| PA (1) | PA8517701A1 (es) |
| PE (1) | PE20011262A1 (es) |
| SV (1) | SV2001000465A (es) |
| TN (1) | TNSN01076A1 (es) |
| UY (1) | UY26731A1 (es) |
| WO (1) | WO2001089570A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005306839A (ja) * | 2003-08-29 | 2005-11-04 | Takeda Chem Ind Ltd | 二環性ピペラジン化合物およびその用途 |
| US7795267B2 (en) | 2003-08-29 | 2010-09-14 | Takeda Pharmaceutical Company Limited | Bicyclic piperazine compound having TGR23 antagonistic activity |
| EP1757290A1 (en) * | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| ES2602789T3 (es) | 2007-02-09 | 2017-02-22 | Ocera Therapeutics, Inc. | Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina |
| CA2698808A1 (en) | 2007-09-13 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
| PE20091102A1 (es) | 2007-12-17 | 2009-07-25 | Janssen Pharmaceutica Nv | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 |
| EP2431035A1 (en) | 2010-09-16 | 2012-03-21 | Æterna Zentaris GmbH | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors |
| US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
| JP2015525202A (ja) | 2012-05-03 | 2015-09-03 | ノバルティス アーゲー | グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態 |
| AU2021365812A1 (en) | 2020-10-21 | 2023-05-11 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| US11957683B2 (en) | 2021-06-18 | 2024-04-16 | Aligos Therapeutics, Inc. | Bicyclic compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| ATE356139T1 (de) * | 1997-06-25 | 2007-03-15 | Pfizer | Dipeptidderivate zur förderung der sekretion von wachstumshormon |
-
2001
- 2001-04-26 DO DO2001000154A patent/DOP2001000154A/es unknown
- 2001-05-10 EP EP01928149A patent/EP1284753A2/en not_active Withdrawn
- 2001-05-10 CA CA002408036A patent/CA2408036A1/en not_active Abandoned
- 2001-05-10 AU AU2001255013A patent/AU2001255013A1/en not_active Abandoned
- 2001-05-10 JP JP2001585812A patent/JP2003534294A/ja active Pending
- 2001-05-10 WO PCT/IB2001/000815 patent/WO2001089570A2/en not_active Application Discontinuation
- 2001-05-10 BR BR0111002-0A patent/BR0111002A/pt not_active Application Discontinuation
- 2001-05-10 MX MXPA02011554A patent/MXPA02011554A/es unknown
- 2001-05-17 GT GT200100089A patent/GT200100089A/es unknown
- 2001-05-18 US US09/860,786 patent/US20020002137A1/en not_active Abandoned
- 2001-05-23 PE PE2001000472A patent/PE20011262A1/es not_active Application Discontinuation
- 2001-05-24 EC EC2001004082A patent/ECSP014082A/es unknown
- 2001-05-24 TN TNTNSN01076A patent/TNSN01076A1/fr unknown
- 2001-05-24 AR ARP010102481A patent/AR028620A1/es not_active Application Discontinuation
- 2001-05-24 SV SV2001000465A patent/SV2001000465A/es unknown
- 2001-05-24 PA PA20018517701A patent/PA8517701A1/es unknown
- 2001-05-25 UY UY26731A patent/UY26731A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001255013A1 (en) | 2001-12-03 |
| WO2001089570A3 (en) | 2002-06-20 |
| BR0111002A (pt) | 2003-04-15 |
| GT200100089A (es) | 2002-01-11 |
| ECSP014082A (es) | 2002-04-23 |
| CA2408036A1 (en) | 2001-11-29 |
| TNSN01076A1 (fr) | 2005-11-10 |
| US20020002137A1 (en) | 2002-01-03 |
| JP2003534294A (ja) | 2003-11-18 |
| PA8517701A1 (es) | 2002-12-30 |
| UY26731A1 (es) | 2001-12-28 |
| DOP2001000154A (es) | 2002-05-15 |
| AR028620A1 (es) | 2003-05-14 |
| WO2001089570A2 (en) | 2001-11-29 |
| EP1284753A2 (en) | 2003-02-26 |
| MXPA02011554A (es) | 2003-04-25 |
| PE20011262A1 (es) | 2001-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Martín et al. | Olanzapine in treatment-refractory schizophrenia: results of an open-label study | |
| CO6361928A2 (es) | Modulares de aril metil benzoquinazolinona alostericos positivos del receptor m1 | |
| EA200600820A1 (ru) | Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина | |
| PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
| SV2001000465A (es) | Combinacion de secretagogos de hormona del crecimiento y antidepresivos ref. pc10733/20144/bb | |
| NO20055531L (no) | Preparat for forbedret kognisjon og hukommelse | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| ES2742373T3 (es) | Una composición de combinación | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| RU2020107732A (ru) | Схема дозирования модулятора s1p с немедленным высвобождением | |
| MX2008013635A (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. | |
| RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
| CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
| CO5251425A1 (es) | Metodo y composiciones para administrar taxanos oralmente a pacientes humanos | |
| RU2005131578A (ru) | Аплидин для лечения множественной миеломы | |
| DE60204694D1 (de) | Kombinationstherapie zur behandlung von herzinsuffizienz | |
| Grossi et al. | NSAID ionisation in the management of soft-tissue rheumatism: role played by the drug, electrical stimulation and suggestion | |
| Buffaloe et al. | A study of combined therapy with stelazine and" Parnate"(SKF 385) in chronic anergic schizophrenics | |
| PT1251850E (pt) | Utilizacao de uma preparacao de combinacao na terapia do cancro | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| ES2668943T3 (es) | Composición farmacéutica para tratar eyaculación precoz y método de tratamiento de la eyaculación precoz | |
| AR047154A1 (es) | Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol | |
| Lässker et al. | Ossification disturbances in children under antiepileptic treatment | |
| Zuccoli et al. | Paliperidone for the treatment of ketamine-induced psychosis: a case report | |
| JP7034314B2 (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 |